

CURRICULUM VITAE

Craig F. LaForce, MD, CPI

OFFICE: North Carolina Clinical Research
2615 Lake Drive
Suite 301
Raleigh, NC 27607

(919) 881-0309 Research
(919) 881-9899 Fax Number

EDUCATION:

1964-1968 BS (Astronomy) Northwestern University, Evanston, IL
1968-1971 MS (Astrophysics) University of Florida, Gainesville, FL
1971-1975 MD Jefferson Medical College, Philadelphia, PA
1975-1978 Residency (Pediatrics) University of North Carolina at Chapel Hill, NC
1978-1980 Postdoctoral 1980 (Pediatric/Adult Allergy & Immunology) National Jewish Hospital/National Asthma Center


ACADEMIC AFFILIATION:

1980-Present Clinical Professor, Division of Allergy, Immunology & Environmental Medicine in the Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC

EMPLOYMENT HISTORY

1986-Present Clinical Research - Medical Director, North Carolina Clinical Research, Raleigh, NC
1980-2016 Private Practice of Allergy and Asthma, Carolina Allergy and Asthma Consultants, PA, Raleigh and Cary, NC
1980-1992 Director of Pediatric Allergy Clinic, University of North Carolina at Chapel Hill, Chapel Hill, NC

Revised 07-Jan-2020


1/07/2020

BOARD CERTIFICATION/LICENSURE:

North Carolina Medical License No. 24437

Diplomate of the American Board of Pediatrics, 1980

Diplomate of the American Board of Allergy and Immunology, a Conjoint Board of the American Board of Internal Medicine and the American Board of Pediatrics, 1985

Certified Physician Investigator (CPI) (Since 10/17/2008)

PROFESSIONAL SOCIETIES:

American Academy of Asthma, Allergy & Immunology (Fellow)

American College of Asthma, Allergy & Immunology (Fellow)

American Thoracic Society

AOA - Medical Honorary

North Carolina Society of Allergy and Clinical Immunology
Secretary/Treasurer 1989-2015

CRN Clinical Research Network, LLC

Drug Information Association

PROFESSIONAL SERVICES:

Served as medical reviewer for:

- *Pediatrics*
- *Pediatric Asthma*
- *Chest*
- *American Journal of Medicine*
- *Journal of Pediatrics*
- *American Society of Health System Pharmacist Drug Information*
- *The American Journal of Managed Care*
- *Annals of Allergy, Asthma & Immunology*

PUBLICATIONS:

1. LaForce CF, Miller MF, Chai H: Effect of erythromycin on theophylline clearance in asthmatic children. *J. of Pediatr.* 99:153, 1981. Presented at American Academy of Allergy and Immunology, March 1981.
2. LaForce CF, Szeffler SJ, Miller MF, Ebling W, Jusko WJ: Inhibition of Methyl prednisolone elimination in the presence of erythromycin therapy. *J. Allergy Clin. Immun.* 72:34, 1983. Presented at the American Academy of Allergy and Immunology, March 1983.
3. Hamrick JH, Jennette JC, LaForce CF: Kimura's Disease: Report of a pediatric case in the United States. *J. Allergy Clin. Immun.* 73:561, 1984.
4. Pierson WE, LaForce CF, Bell TD, MacCosbe PE, Sykes RS, Tinkleman D: Long-term double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescent and adult asthmatics. *J. Allergy Clin. Immun.* 1990, 85(3):618-26. Presented at the American Academy of Allergy and Immunology, March 1989.
5. Meltzer EO, Orgel HA, Bronsky EA, Furakawa CT, Grossman J, LaForce CF, Lemanske RF, Paull BR, Pearlman DS, Ratner PH, Spector SL, Tinkleman D, VanAs A, Rogenes PR: A dose ranging study of fluticasone propionate aqueous nasal spray for seasonal rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. *J. Allergy Clin. Immun.* 1990, 86(2):221- 30. Presented at the American Academy of Allergy and Immunology, March 1989.
6. Nathan R, Bronsky E, Fireman P, Grossman J, LaForce C, Lemanske RF, Pearlman D, Ratner P: A study of once-versus-twice daily intranasal fluticasone propionate in the treatment of seasonal rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. *J. Allergy Clin. Immun.* 86:221, 1990. Presented at the American Academy of Allergy and Immunology, March 1989.
7. Nathan RA, Bronsky EA, Fireman P, Grossman J, LaForce CF, Lemanske RF Jr, Pearlman DS, Ratner PH, Rogenes PR: Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. *Annals of Allergy* 1991 Sep; 67(3):332-8.
8. Pearlman DS, Chervinsky P, LaForce CF, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW, Cocchetto DM, Alexander WJ, vanAs A: A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. *N. Eng. J. Med.* 327:1420-1425, November 1992. Presented to AAAAI, 1991.
9. Winder J, Bell T, Brodsky L, English G, LaForce CF, Lopex M, Welch M, Feiss G, Tobey R, Smith J: A comparative study of intranasal triamcinolone acetonide aerosol and intranasal beclomethasone dipropionate aqueous spray in perennial allergic rhinitis. *Immun. and Aller. Practice* 15:203, 1993.

10. LaForce CF, Ellis EF, Kordansky DW, Cocchetto DM, Sharp JT: Use and acceptance of ventolin Rotacaps® and the Rotahaler® in 1235 asthmatic patients. *Clinical Therapeutics, Vol 15:2, March-April 1993, P321-29.*
11. Chervinski P, vanAs A, Bronsky EA, Dockhorn R, Noonan M, LaForce CF, Pleskow W: Fluticasone propionate aerosol for the treatment of adults with mild-to-moderate asthma. *J. Allergy Clin. Immunol. 1994; 94(4):676-683.*
12. Banov CH, Woehler TR, LaForce CF, Pearlman DS, Blumenthal MN, Miller MF, Morgan WF, Frazer H, Southern DL, Gold B, Field E, Rogenes PR: Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. *Annals of Allergy 1994;73(3):240-6.*
13. LaForce CF, Dockhorn RJ, Findlay SR, Meltzer EO, Nathan RA, Stricker W, Weakley S, Field EA, Rogenes PR: Fluticasone propionate is more effective than beclomethasone dipropionate for seasonal allergic rhinitis in adults and adolescents. *J of Fam Pract; Vol. 38, No.2, (Feb.), 1994.*
14. Sheffer AL, LaForce C, Chervinsky P, Pearlman D, Schaberg A, and the Fluticasone Propionate Asthma Study Group: Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. *J Fam Pract 1996; 42:369-75.*
15. LaForce CF, Dockhorn RJ, Prenner BM, Chu TJ, Kraemer MJ, Widlitz MD, D'Eletto TA, Freitag J: Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: A 4-week comparative multicenter trial. *Annals of Allergy, Asthma & Immunology, February 1996, 76:181.*
16. Munk Z, LaForce C, Furst J, Simpson B, Feiss G, Smith J: Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. *Annals of Allergy, Asthma & Immunology, October 1996, 77:277-281.*
17. Allen DB, Bronsky EA, LaForce CF, Lawrence M, Nathan RA, Tinkleman DG, Vandewalker ML, Konig P, and the Fluticasone Propionate Asthma Study Group: Growth in asthmatic children treated with fluticasone propionate. *Journal of Pediatrics, March 1998, 1-6.*
18. LaForce C, Pearlman DS, Ruff M, Silvers WS, House KW, Brown A, Hamedani AG: Fluticasone propionate powder-administration via diskus inhaler once daily or twice daily to pediatric patients with moderate persistent asthma. *Presented at Annual Meeting of the American Academy of Allergy, Asthma and Immunology, February 1997.*
19. Casale TB, Bernstein IL, Busse W, LaForce CF, Tinkleman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB, Adelman DC: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. *J. Allergy Clin. Immunol. 100:1, February 1997, 100-21.*

20. Shapiro G, Bronsky EA, LaForce CF, Mendelson L, Pearlman D, Schwartz RH, Szeffler SJ: Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. *The Journal of Pediatrics*, June 1998, Vol 132, Number 6: 976-982.
21. Sorkness CA, LaForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR: The effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-asthma axis in adult patients with asthma. *Clinical Therapeutics*, Vol 21, Number 2, February 1999.
22. Bernstein DI, Berkowitz RB, Chervinsky P, Dvorin DJ, Finn AF, Gross GN, Karetzky M, Kemp JP, LaForce C, Lumry W, Mendelson LM, Nelson H, Pearlman D, Rachelefsky G, Ratnor P, Repsher L, Segal AT, Selner JC, Settipane GA, Wanderer A, Cuss FM, Nolop KB, and Harrison JE: Dose-ranging study of a new steroid for asthma: Mometasone furoate dry powder inhaler. *Respiratory Medicine*, Vol 93, p 603-612, 1999.
23. LaForce C: Use of nasal steroids in managing allergic rhinitis. *Journal of Allergy and Clinical Immunology*, Vol 103: Number 3, Pt 2, S388-393, March 1999.
24. Kavuru M, Melamed J, Gross G, LaForce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T: Salmeterol and fluticasone propionate combined in a new dry powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*, Vol 105, Number 6, Pt 1, 1109-1116, June 2000.
25. LaForce CF, Pearlman DS, Ruff ME, Silvers WS, Weinstein SW, Clements DS, Brown A, Duke S, Harding SM, House KW: Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. *Annals of Allergy, Asthma & Immunology*, Vol 85(5), November 2000.
26. Pleskow W, LaForce CF, Yegen U, Matos D, Cioppa GD: Formoterol delivered via the dry powder aerolizer™ inhaler versus albuterol MDI and placebo in mild to moderate asthma: a randomized, double-blind, double-dummy trial. *Journal of Asthma*, November 2003 Vol.40,No.5,pp.505-514.
27. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Cioppa GD: Effect of Omalizumab on symptoms of seasonal allergic rhinitis. *JAMA*, Vol 286, No 23, December 19, 2001.
28. vanAdelsberg J, LaForce CF, Weinstein SF, Menten J, Malice MP, Philip G, Reiss TF, and the Montelukast Spring Rhinitis Investigator Group: Randomized controlled trial evaluating clinical benefit of montelukast for treating spring seasonal allergic rhinitis. *Annals of Allergy, Asthma and Immunology*, Vol 90, February, 2003, pp 214-222.

29. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, Townley RG, and the Pulmicort Turbuhaler® Study Group (LaForce C, et al.): Budesonide delivered by Turbuhaler® is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. *J Allergy Clin Immunol April 1998; 101:457-63.*
30. Nelson HS, Busse WW, deBoisblanc BP, Berger WE, Noonan MJ, Webb DR, Wolford JP, Mahajan PS, Hamedani AG, Shah T, Harding SM, the Fluticasone Propionate Study Group (LaForce CF, et al.): Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. *Presented at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, San Francisco, CA February 1997. Submitted to J. Allergy Clin. Immunol. 1998.*
31. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, Becker A, for the Pediatric Montelukast Study Group (LaForce CF, et al): Montelukast for chronic asthma in 6 – to 14 – year-old children. *Journal of the American Medical Association, Vol 279, pp. 1181- 1186, April 15, 1998.*
32. Meltzer E, and the Rhinocort Aqua Study Group (LaForce CF, et al.): Clinical and anti-inflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. *Presented at the March 1997 meeting of the AAAAI. Submitted to Annals of Allergy Asthma & Immunology, May 1998.*
33. Berger WE, Fineman SM, Lieberman P, Miles RM, and the Rhinitis Study Groups: Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. *Annals of Allergy, Asthma & Immunology, Vol 82, June 1999.*
34. Condemi J, Schulz R, Lim J and the TAA Study Group: Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. *Ann Allergy Asthma Immunol, Vol 84:533-538, May 2000.*
35. Banov CH, Lieberman P, and members of vasomotor rhinitis study group: Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. *Annals of Allergy, Asthma & Immunology, Vol 86, January, 2001.*
36. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF, and Montelukast Fall Rhinitis Investigator Group: Efficacy and tolerability of Montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. *Annals of Allergy, Asthma & Immunology, Vol 88, No. 6, June 2002.*
37. LaForce C, Corren J, Wheeler WJ, Berger WE and the Rhinitis Study Group: Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. *Annals of Allergy, Asthma & Immunology, 2004 Aug; 93(2): p 154-9.*

38. Wolfe J, LaForce C, Friedman B, Sokol W, Orevillo C, Ziehmer B, Till D, Stenglein S, Cioppa, GD: Formoterol 24 µg b.i.d. is not associated with increased serious asthma-related adverse events compared with formoterol 12 µg b.i.d. and placebo. *Journal of Asthma*, November 2004.
39. Weiler J, Nathan R, Rupp N, Kalberg C, Emmett A, Dorinsky P, with acknowledgments to LaForce C, et al for expertise and contribution: Effect of Fluticasone/Salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. *Ann Allergy Asthma Immunol*. January 2005; Vol 94, p 65-72.
40. Schenkel E, LaForce C, Gates D: Mometasone furoate nasal spray is effective in relieving the ocular symptoms associated with seasonal allergic rhinitis. *Ear, Nose & Throat Journal*, May 16, 2005.
41. Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, Dorinsky P: The safety of twice-daily treatment with Fluticasone propionate and Salmeterol in pediatric patients with persistent asthma. *Annals of Allergy, Asthma & Immunology*, Vol 95, July 2005, p 66-71.
42. Pearlman D, Berger W, Kerwin E, LaForce C, Kundu S, Banerji D: Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. *J Allergy Clin Immunol*, December 2005, pp 1206-1212.
43. LaForce C, Prenner B, Andriano K, Lavecchia C, Yegen U: Efficacy and safety of Formoterol delivered via a new multidose dry powder inhaler (Certihaler™) in adolescents and adults with persistent asthma. *Journal of Asthma*, 42: 101-106, 2005.
44. LaForce C: Review of the pharmacology, clinical efficacy, and safety of azelastine hydrochloride. *Expert Review of Clinical Immunology*, Vol 1, No 2, July 2005, pp 191-201.
45. Lumry W, Conway M, LaForce C, Pearlman D, Scott C, Herje N, Wu W, Crim C: Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled steroids. *Annals of Allergy, Asthma & Immunology*, Vol 96, January 2006, pp 51-59.
46. Nathan R, Finn A, LaForce C, Ratner P, Chapman D, de Guia E, Hewlett D, Kramer B: Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. *Annals of Allergy, Asthma & Immunology*, Vol 97, September 2006, p 389-396.
47. Wolfe J, LaForce C, Friedman B, Sokol W, Till D, Della Cioppa G, van As A: Formoterol, 24 µg bid, and serious asthma exacerbations: similar rates compared with Formoterol, 12 µg bid, with and without extra doses taken on demand, and placebo. *Chest* 2006; 129; 27-38.
48. LaForce C, Man C, Henderson F, McElhaney J, Hampel F, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A: Efficacy and safety of inhaled Zanamivir in the prevention of influenza

in community-dwelling, high-risk adult and adolescent subjects: A 28-day, multicenter, randomized, double-blind, placebo-controlled trial. *Clinical Therapeutics, Volume 29, Number 8, p 1-12, August 2007.*

49. Patel P, Philip G, Yang W, Call R, Horak F, LaForce C, Gilles L, Garrett G, Dass S, Knorr B, Reiss T: Randomized, double-blind, placebo-controlled study of Montelukast for treating perennial allergic rhinitis. *Annals of Allergy, Asthma & Immunology, Vol 95, December 2005, p 551-558.*
50. Meltzer E, Kunjibetty S, Hall N, Wingertzahn M, Murcia C, Berger W, LaForce C: Efficacy and safety of ciclesonide, 200 µg once daily, for the treatment of perennial allergic rhinitis. *Annals of Allergy, Asthma & Immunology, Vol 98, February, 2007, p 175-180.*
51. LaForce C, Alexander M, Deckelmann R, Fabbri L, Aisanov Z, Cameron R, Owen R, Higgins M: Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. *Allergy 2008, 63, p 103-111.*
52. Berger WE, Nayak A, Lanier BQ, Kaiser HB, LaForce C, Darken P, Hall N, Wingertzahn M: Efficacy and safety of once-daily ciclesonide nasal spray in children with allergic rhinitis. *Pediatric Asthma, Allergy and Immunology, Vol 21: May 19, 2008, p 73-82.*
53. Zhou H, Tang Y, Alexis N, Almond M, Donohue J, LaForce C, Bromberg P, Peden D: Influence of the C-159T single nucleotide polymorphism of the CD14 gene promoter on lung function in smokers with chronic bronchitis. *Respiratory Medicine (2009) XX, p 1-8.*
54. Kaliner MA, Storms W, Tilles S, Spector S, Ricardo T, LaForce C, Lanier BQ, Chipps B: Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 µg in the treatment of allergic rhinitis. *Allergy and Asthma Proceedings (AAP) 30:1-00, April 2009.*
55. LaForce C, Korenblat P, Osborne P, Dong F, Higgins M: 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. *Current Medical Research and Opinions, Vol. 25, No. 10, August 2009, p 2353-2359.*
56. LaForce C, van Bavel J, Meltzer EO, Wingertzahn MA: Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis. *Annals of Allergy, Asthma & Immunology, Vol. 103, August, 2009, p 166-173.*
57. Shah S, Berger W, Lumry W, LaForce C, Wheeler W, Sacks H: Efficacy and safety of Azelastine 0.15% nasal spray and Azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. *Allergy and Asthma Proceedings (AAP) 30, No. 6, November-December 2009, p 628-633. Also presented at the scientific meeting of the Aspen Allergy Conference (AAC), Aspen,*

Colorado, July, 2009.

58. LaForce C, Aumann J, ParrenoL, Iqbal A, Young D, Owen R, Higgins M, Kramer B,: Sustained 24-hour efficacy of once daily indacaterol (300 µg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study. *Pulmonary Pharmacology & Therapeutics* 24 (2011) 162-168.
59. Nelson H, Bonuccelli C, Radner F, Ottosson A, Carrol K, Andersson T, and LaForce C: Safety of formoterol in patients with asthma: Combined analysis of data from double-blind, randomized controlled trials. *J Allergy Clin Immunol February 2010*, p 390-396.e8.
60. Weinstein C, Staudinger H, Scott I, Amar N, LaForce C: Dose counter performance of the Mometasone Furoate/formoterol inhaler in subjects with asthma or chronic obstructive pulmonary disease. *Submitted to the Respiratory Medicine, September 27, 2010.*
61. Vogelmeier C, Magnussen H, LaForce C, Owen R, and Kramer B: Profiling the bronchodilator effects of the novel ultra-LABA indacaterol against established treatments in COPD. *Pulmonary Pharmacology & Therapeutics* July 21, 2010.
62. Li J, Qaqudah P, Weinstein S, LaForce C, Ellsworth A, Ortega H, and Ferro T: Fluticasone propionate/salmeterol combination in children with asthma: Key cardiac and overall safety results. *Clinical Research and Regulatory Affairs, 2010; 27(3): p 87- 95.*
63. Parker J, Oh C, LaForce C, Miller D, Pearlman D, Le C, Robbie G, White W, White B, and Molfino N: Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. *Submitted to BMC Pulmonary Medicine, September 2010.*
64. van Noord J, Buhl R, LaForce C, Martin C, Jones F, Dolker M, Overend T: QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. *Thorax Online First, October 26, 2010, p 1-6.*
65. LaForce C, Carr W, Tilles S, Chipps B, Storms W, Meltzer E, and Edwards M: Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. *Allergy Asthma Pro 31:132-140, 2010.*
66. Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Moltino NA, for the MEDI-528 Clinical Trials Group: Safety profile and clinical activity of multiple subcutaneous doses of MEDI-G28, a humanized anti-interleukin-monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. *BMC Pulmonary Medicine, Vol II, 28 February 2011.*

67. Weinstein C, Standinger H, Scott I, Amar NJ, LaForce C: Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. *Respiratory Medicine*, March 2011, xx 1-10.
68. Lieberman P, Meltzer EO, LaForce CF, Darter AL, Tort MJ: Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. *Allergy and Asthma Proceedings*, Vol 32, No 2, March-April 2011, p 151-158.
69. Meltzer EO, Kuna P, Nolte H, Nayak AS, LaForce CF on behalf of the P04073 Study Investigators: Mometasone furoate/formoterol reduces asthma deteriorations and improves lung functions. *European Respiratory Journal*, April 2011.
70. LaForce C, Weinstein C, Nathan RA, Weinstein SF, Standinger H, Meltzer EO: Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination. *Journal of Asthma*, Early Online, July 2011, p 1-7.
71. Mohar D, Berger W, LaForce C, Raphael G, Desai S, Huang H, and Hinkle J: Efficacy and tolerability of ciclesonide nasal aerosol in patients with perennial allergic rhinitis. *Allergy and Asthma Proceedings*, January-February 2012, Vol 33, No 1, p 19-26.
72. LaForce C, Journeay G, Miller D, Silvey M, Wu W, Lee L, Chylack L: Ocular Safety of Fluticasone Furoate nasal spray in patients with perennial allergic rhinitis: A Two-Year Study. *Ann Allergy Asthma Immunol* 111 (2013), p 45-50.
73. Meltzer EO, Jacobs RL, LaForce CF, Killey L, Dunbar SA, Tantry SK: Once daily treatment with Beclomethasone Dipropionate Hydrofluoro-alkane nasal aerosol is safe and effective in subjects with perennial allergic rhinitis. *Presented at annual scientific meeting of the American College of Allergy, Asthma & Immunology*, Nov 2011, Boston, MA. *Allergy & Asthma Proceedings*. March-April 2012, Vol 33, p 1-9.
74. Berger W, Mohar D, LaForce C, Miller D, Silvey M, Wu W, Lee L, Chylack L: A 26-week tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis. *American Journal of Rhinology & Allergy*, July-August 2012, Vol 26, No 4, p 302-307.
75. Meltzer E, LaForce C, Ratner P, Price D, Ginsberg D, Carr W: MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomization, double-blind, placebo-controlled trial of efficacy and safety. *Allergy & Asthma Proceedings*, July-August 2012, Vol 33, No 4, p 324-331.

76. Pearlman D, LaForce CF, Kaiser K: Fluticasone/formoterol combination therapy significantly improves lung function compared with monotherapy in adolescent and adult patients with mild to moderate asthma. *Submitted to Clinical Therapeutics, Oct 2012.*
77. Vogelmeier C, LaForce C, Owen R, Kramer B: Profiling the bronchodilator effects of the novel ultra-LABA indacaterol against established treatments in COPD. *Submitted to Therapeutics Advances in Respiratory Disease, Oct. 2012.*
78. LaForce C, Colice G, Miller D, Lankford A, Gallipolis S, Reed C, Williams S, Kajdasz D: A randomized double-blind, placebo-controlled, pilot study of the safety of apadenoson in subjects with mild or moderate asthma. *Submitted to Journal of Nuclear Medicine, October 12, 2012.*
79. LaForce C, Colice G, Miller D, Lankford A, Gallipolis S, Reed C, Williams S, Kajdasz D: A randomized double-blind, placebo-controlled, pilot study of the safety of apadenoson in subjects with moderate to severe chronic obstructive pulmonary disease. *Submitted to Journal of Nuclear Medicine, October 12, 2012.*
80. Pearlman DS, LaForce CF, Kaiser K: Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. *Clinical Therapeutics, S0149-2918, August 2013, 00258.*
81. Beeh KM, LaForce CF, Gahlemann M, Wenz A, Toorawa R, Flezar M: Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma. *Respiratory Research, September 2013, p 1-39.*
82. Skoner DD, LaForce CF, Nathan RA, Urdaneta ER, Zielinski MA, Sacavage SD, Franklin KB, Wu MM: Effect of Cetirizine on symptom severity and quality of life in perennial allergic rhinitis. *Allergy & Asthma Proceedings, July-Aug 2014; 35 (4); 338-45.*
83. LaForce C, Miller D, Taveras H, Iverson H, O'Brien C, Raphael G: Albuterol multidose dry powder inhaler in subjects 12 years and older with persistent asthma: 12- and 52- week safety. *Presented (article and poster) at the ACAAI Annual Meeting, Atlanta, Georgia, November 6-10, 2014.*
84. Feldman GJ, Bernstein JA, Hamilton A, Nivens MC, Korducki L, LaForce C: The 24-h FEV₁ time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies. *Springer Plus Journal, Aug 9, 2014, 3:419; doi: 10.1186/2193-1801-3-419.*
85. Castro M, King TS, Kunselman SJ, Cabana MD, Denlinger L, Holguin F, Kazani SD, Moore WC, Moy J, Sorkness CA, Avila P, Bacharier LB, Bleeker E, Boushey HA, Chmiel J, Fitzpatrick AM, Gentile D, Hundal M, Kraft M, Krishnan JA, LaForce C, Lazarus SC, Lemanske R, Lugogo N, Martin RJ, Mauger DT, Naureckas E, Peters SP, Phipatanakul W, Que LG, Sheshadri A, Smith L, Solway J, Sullivan-Vedder L, Sumino K, Wechsler ME, Wenzel S, White SR,

- Sutherland ER, National Heart, Lung, and Blood Institute's AsthmaNet: Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. *JAMA*, May, 2014; 311 (20): 2083-91. Doi: 10.1001/jama.2014.5052.
86. Beeh K, LaForce C, Gahlemann M, Wenz A, Toorawa R, and Flezar M: Randomized, double-blind, placebo-controlled crossover study to investigate different dosing regimens of Olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma. *Respiratory Research*, July 2015; Vol 16:87 doi: 10.1186/s12931-015-0243-1.
 87. LaForce C, Pearle J, Feldman G, Spangenthal S, Eckert J, Mota F, Henley M, Patalano F, D'Andrea P: Efficacy and safety of twice-daily Glycopyrronium in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: The GEM1Study. *International Journal of COPD* 2016: 11, p 1233-1243.
 88. Alving K, Anolik R, Crater G, LaForce C, Rickard K: Validation of a new portable exhaled nitric oxide analyzer: Randomized studies in asthma. *Pulmonary Therapeutics*, June 2016.
 89. Ferguson GT, Fitzgerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, on behalf of the BISE study investigators: Benralizumab for mild to moderate, persistent asthma: The BISE Phase III Study. *Lancet Respiratory Medicine* 201. Published online May 22, 2017 ([http://dx.doi.org/10.1016/S2213-2600\(17\)30190-x](http://dx.doi.org/10.1016/S2213-2600(17)30190-x)).
 90. LaForce C, Taveras H, Iverson H, Shore P: Albuterol multidose powder inhaler efficacy and safety versus placebo in children with asthma. *Allergy and Asthma Proceedings*, 37: p 1-10, 2016; doi: 10.2500/aap.2016.37.401; and January-February 2017, Vol 38, No.1, p 28-37, doi:10.2500/aap.2017.38.4015). Also presented at AAAAI scientific meeting held in Los Angeles, CA March 4-7, 2016.
 91. Kerwin E, LaForce C, Pedinoff A, Yadao A, D'Andrea P, Uddin A, Franke-Bray B: Cardiovascular safety of twice-daily inhaled Glycopyrrolate in subgroups of patients with moderate-to-severe COPD: pooled analysis from the GEM1, GEM2 FLIGHT1 and FLIGHT2 studies. *American Journal of Respiratory and Critical Care Medicine*, 2016; 193; A6794.
 92. D'Andrea P, LaForce C, Pedinoff A, Miller D S, Yadao A, Uddin A, Franke-Bray B: Safety of inhaled Glycopyrrolate in patients with moderate-to-severe COPD: Subgroup analysis from the pooled data of four clinical trials. *American Journal of Respiratory and Critical Care Medicine*, 2016; 193; A6793.
 93. LaForce C, Derom E, Bothner U, Kloer I M, Trampisch M, Buhl R: Long-term safety of tiotropium/Olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies. *International Journal of COPD* 2018:13 pp 1819-1831.

NON-REFEREED JOURNALS:

1. LaForce CF: The cluster of galaxies Abell 2256. University of Florida Press, 1970.
2. LaForce CF: Theophylline: New thoughts on an old drug. *AM. J. of Asthma and Allergy for Pediatr.* 2:43, 1988.

ABSTRACTS:

1. LaForce CF, Kaliskar A, Miller MF, Wilkins J: Effect of erythromycin base on theophylline pharmacokinetics in asthmatic children. *J. Allergy Clin. Immun.* 71:171, 1983. Presented at the American Academy of Allergy and Immunology, March 1983.
2. LaForce CF, Davis V: Nasal septal perforation with intranasal beclomethasone. *J. Allergy Clin. Immun.* 75:186, 1985. Presented at the American Academy of Allergy and Immunology, March 1985.
3. Shotwell MJ, LaForce CF, Dunn KD, Rubinoopk, Cocchetto DM: Resolution of errors in laboratory tests which rate-limit enrollment in clinical trials: An example via test of adrenal cortical function. *J. Clin. Res. Drug Dev.*, June 1989.
4. Schoenwetter W, Silvers WS, Winder JA, Lumry WR, LaForce CF, Cohen R, Leonardy G, Gilner DG, Ratner P, Lim J, Stokes A, McNally C: Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of seasonal allergic rhinitis. *ACAAI Annual Meeting, 1995:A37.*
5. Bronsky E, Dockhorn R, Meltzer E, Shapiro G, Boltansky H, LaForce CF, Ransom J, Weiler J, Blumenthal M, Weakley S, Wisniewski M, Field E, Rogenes P: Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in seasonal allergic rhinitis. *ACA Annual Meeting, 1995:P36.*
6. Adelglass JM, Banov C, LaForce C, Wanderer A, Weiler J, Peskind SP, Drda KD, Wood CW: Randomized, double-blind, parallel comparison of Atrovent nasal spray 0.03% versus placebo administered twice a day in patients with allergic (APR) or nonallergic (NAPR) perennial rhinitis. *ACAAI Annual Meeting, 1995:P21.*
7. Wolfe J, LaForce C, Chervinsky P, Galant S, Lumry W, Noonan M, Pearlman D, Seltzer J, Arledge T, Byrne A, Liddle R: Inhaled salmeterol powder compared with albuterol aerosol given regularly or as needed for asthma. *ACAAI Annual Meeting, 1995:A9.*
8. Grossman J, Banov C, Bierman C, Bronsky E, Dvorin D, Georgitis J, LaForce C, Lockey R,

- Munk Z, Ethessabian R, Wood C: Long-term treatment of nonallergic rhinitis (NAPR) with ipratropium bromide (IB) nasal spray 0.06% and 0.12%. *ACAAI Annual Meeting, 1995:P19.*
9. Georgitis JW, Banov CH, Bierman CW, Bronsky E, Dvorin D, Ethessabian R, Grossman J, LaForce C, Lockey R, Munk Z, Weakley S, Love J, Roszko P, Wood C, Zegarelli C: Efficacy and safety of ipratropium bromide nasal spray in nonallergic rhinitis: Comparison of 84 mcg and 168 mcg bid to placebo. *ACAAI Annual Meeting, 1995: P19.*
 10. LaForce C, Liddle RF, Yancey SW: Salmeterol response in asthmatic patients using inhaled corticosteroids and in those not using inhaled corticosteroids. *ACAAI Annual Meeting, 1995:P89.*
 11. LaForce C, Sharp JT, Mitchell R, Kalberg CJ, Aaronson DW: A comparison of beclomethasone aqueous nasal spray with terfenadine for the treatment of seasonal allergic rhinitis. *American Academy of Allergy and Immunology, March 1995:658.*
 12. Mellon M, Bronsky E, Ellis M, Fries S, Gillespie D, Ginchansky E, Kornfeld S, LaForce C, Smith T, Thomas MR: Children (6-12 years) with mild, episodic asthma benefit from qid nedocromil sodium (NED). *American Academy of Allergy and Immunology, February 1995:699.*
 13. Pearlman DS, Chervinsky P, Howland WC, Kemp J, LaForce C, Montealegre F, Pollard SJ, Prenner B, Weinstein SF, Wolfe J, Stahl EG, Arledge T, Furlong A, Byrne A: Inhaled salmeterol powder compared with placebo administered over 12 weeks to children with mild-to-moderate asthma. *American Journal of Respiratory and Critical Care Medicine, Vol 153, No.4, April 1996:A76.*
 14. Dockhorn R, Bronsky E, Chervinsky P, Cohen R, Ethessabian R, Finn A, Grossman J, Howland W, Kaiser H, LaForce C, Lumry W., Munk Z, Pearlman D, Pollard S, Ratner P, Settupane G, Sim T, Storms W, Webb R, Drda K, Wood C: Randomized, double-blind, six-week placebo-controlled (V), parallel comparison of Atrovent nasal spray 0.03% (A) alone, Beconase AQ (B) alone, and the combined use of A with B in patients with allergic and non-allergic perennial rhinitis (APR and NAPR). *American Journal of Respiratory and Critical Care Medicine, Vol. 153, No.4, (April) 1996; A525*
 15. Chervinsky P, Ginchansky E, Ayars G, LaForce C, Taylor J, Rogenes P, Schaberg A, Wisniewski M, Pepsin PJ: Fluticasone propionate 500 mcg/day is superior to triamcinolone acetone 800 mcg/day in controlling asthma. *The European Respiratory Journal, Vol 9: Supplement 23:P0526-78s. Presented at the ERS Annual Congress, September 8, 1996.*
 16. LaForce C, Goldstein M, Storms W, Levy B, Li J, Littlejohn T, McClusky D, Lincourt W, Rogenes P, Schaberg A, Wisniewski M: Comparison of inhaled fluticasone propionate (FP) and flunisolide (FLN) effects on the HPA axis as assessed by 6-hour cosyntropin infusion testing.

The European Respiratory Journal, Vol 9: Supplement 23, 1065-163s. Presented at the ERS Annual Congress, September 9, 1996.

17. Storms W, Howland WC, Sorkness CA, LaForce C, Goldstein M, Lincourt WR, Rogenes PR, Schaberg AE, Edwards L, and the FP HPA Axis Clinical Study Group: Fluticasone propionate (FP), triamcinolone acetonide (TAA) and flunisolide (FLN) have similar effects on the HPA axis. *J. Allergy Clin.Immunol. 99: S318, January 1997. Presented at the American Academy of Allergy and Immunology, February 1997.*
18. Berger W, Busse W, LaForce C, Weinstein S, Wolford J, Hamedani A, Mahajan P, Harding S: Fluticasone propionate is effective in reducing oral prednisone requirements and improving lung function and quality of life in patients with severe chronic asthma. *Submitted to European Respiratory Society, Annual Meeting, 1997.*
19. Maier WC, Rongling L, LaForce CF: Validation of the ISAAC asthma questionnaire for parents of children aged 5-9 years. *Presented at the 13th Annual Meeting of the International Society of Pharmacoepidemiology, August 25, 1997.*
20. Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G: Bronchodilatory effect of foradil versus albuterol MDI and placebo over a 12-week treatment period. *Presented ATS Annual Meeting, 1997 and American College of Allergy, Asthma and Immunology Annual Meeting, November 1997.*
21. Pearlman D, Aaronson D, Bronsky E, Chervinsky P, Cohen R, Dockhorn R, Ehtessabian R, Finn A, Grossman J, Howland W, Kaiser H, LaForce C, Lumry W, Munk Z, Sublett J, Ratner P, Settipane G, Sim T, Storms W, Webb R, Drda K, Wood C: Long-term comparison of ipratropium bromide nasal spray 0.03% vs beclomethasone nasal spray in perennial rhinitis. *Presented at the American College of Allergy, Asthma and Immunology, November 1997.*
22. LaForce C, and the Rhinocort Aqua Study Group: Once-daily administration of Rhinocort® (budesonide) aqua nasal spray versus twice-daily administration of Beconase AQ® (beclomethasone dipropionate) in the long-term treatment of adults with perennial allergic rhinitis. *J. Allergy Clin. Immunol. 101, Number 1, Part 2: 1032, January 1998. Presented at Annual Meeting of AAAAI, March 13-18, 1998.*
23. Malmstrom K, Hebert J, LaForce C, Ringdal NR, Rasmussen B, Peszek I, Ayala C, Reiss TF, for the Montelukast Additivity Group: Montelukast (MK-0476), a leukotriene receptor antagonist provides additional clinical benefit to chronic asthmatic patients using inhaled beclomethasone. *Submitted to the International Asthma Meeting, Barcelona, Spain, 1998.*
24. Nathan R, LaForce C, Mitchell D, Pearlman D, Baitinger L, Woodring A, House K, Prillaman B, Shah T: The salmeterol/fluticasone propionate combination (50/100mcg) via diskus® has a

rapid onset of effect in asthma patients on salmeterol or inhaled corticosteroids. *Presented at the American Thoracic Society Meeting, April 23-28, 1999.*

25. LaForce CF: Once-daily budesonide (Pulmicort Turbuhaler®) is effective in asthmatic Adults not maintained on corticosteroids. *Respiratory & Critical Care Medicine, Vol 159, Number 3, A629, March 1999. Presented at the American Thoracic Society Meeting April 23-28, 1999.*
26. LaForce CF, Goode-Sellers ST, Edwards LD, Richard K, Cook CK: Most discomforting symptoms of sinusitis. *Presented to the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting, November 1998. Presented at the annual meeting of AAAAI, February 25-28, 1999.*
27. Meltzer EO, LaForce CF, Settipane GA, Charous BL, Goode-Stellers ST, Westlund RE, Rickard KA, Cook CK: Symptom relief from an acute episode of recurring sinusitis with fluticasone propionate aqueous nasal spray as adjunctive therapy to cefuroxime axetil. *The Journal of Allergy and Clinical Immunology, Vol 105, Number 1, Pt.2, January 2000. Presented at the annual meeting of AAAAI, March 3-8, 2000, San Diego, CA.*
28. LaForce C, Woodring A, Baitinger L, House K, Prillaman B, Shah T: Salmeterol 50mcg/fluticasone propionate 100mcg diskus combination product demonstrates improvements in lung function regardless of baseline corticosteroid therapy. *Journal of Allergy and Clinical Immunology, Vol. 105, Number 1, Pt. 2, January 2000. Presented at the annual meeting of AAAAI, March 3-8, 2000, San Diego, CA.*
29. Michele TM, Lu S, Malice MP, Malmstrom K, LaForce C, Wolfe J, Meltzer EO, Reiss TF: Combination of montelukast and loratadine in seasonal allergic rhinitis: An analysis of three spring studies. *Journal of Allergy and Clinical Immunology, Vol 105, Number 1, Pt. 2, January 2000. Presented at the annual meeting of AAAAI, March 3-8, 2000, San Diego, CA.*
30. Rippe J, Bonovich K, Colfer H, Davidson M, Dujovne C, Fried D, Greenspan M, King S, Karlberg R, LaForce C, Litt M, McGhee JR: The cholesterol-lowering effect of Cholestin™ in subjects with moderate hypercholesterolemia: A multi-center, self-pairing study. *Abstract of this paper presented in the AHA '99 Cardiovascular Disease Epidemiology & Prevention Meeting, Orlando, FL, March, 1999. Submitted to the Journal of General Internal Medicine, June 2000.*
31. Philip G, Malmstrom K, LaForce CF, Malice M-P, Reiss TF, and the Montelukast Spring Rhinitis Investigator Group: Montelukast in the treatment of nighttime symptoms associated with spring allergic rhinitis in a large, double-blind, randomized, placebo-controlled study. *Abstract submitted to EAACI for May 2001 publication.*
32. Ratner, Gillman S, LaForce C, Nathan R, Raphael G, White T, Chapman D, Hewlett D: A randomized, double-blind parallel group, placebo controlled, multicenter study of the efficacy

and safety of Zyrtec® (cetirizine HCL) syrup vs. Claritin® (loratadine) syrup vs. placebo in the treatment of children with seasonal allergic rhinitis. *June 2002.*

33. LaForce CF, Baker JW, Kaiser HB, Amin D, Rohatagi S, Mendes P, Williams J, Kundu S, Banerji D: Ciclesonide, a novel inhaled steroid, has no effect on HPA-axis function in mild-to-moderate asthmatics. *Presented at the AAAAI meeting, March 2003.*
34. LaForce C, Prenner B, Kottakis J, Andriano K, Laccchia C, Yegen U: A novel multi-dose dry powder inhaler is effective for delivery of formoterol in adolescents and adults with persistent asthma. *ATS publication, 2003.*
35. Frishberg BM, Littlefield D, Allen J, Spruill S, Plachetka J, and the Investigator team who participated in the POZEN studies: A new formulation of DHE is effective for sustaining relief in the acute treatment of migraine. *Poster presented at the American Headache Society meeting, Chicago IL, June 20, 2003.*
36. Rooklin A, Elkayam D, Weiler J, Windom H, Schoaf L, Scott C, House K, Payne JE, Shah T and the Participating Investigator Group: The fluticasone propionate/salmeterol HFA MDI is significantly more efficacious in treating asthma than placebo HFA MDI, fluticasone propionate CFC MDI or salmeterol CFC MDI. *Abstract presented at the annual meeting of the AAAAI held March, 2001.*
37. Nathan R, Mitchell D, Condemi J, Heller A, Schoaf L, Herrle M, Scott C, Payne JE, House K, Shah T and participating investigator teams: Cardiovascular and hypothalamic – pituitary – adrenal axis safety of fluticasone propionate / salmeterol HFA MDI in adolescent and adult patients with asthma. *Presented at the annual meeting of the American Thoracic Society in San Francisco, CA held May 23, 2001.*
38. LaForce C, Corren J, Wheeler WJ, and members of the Rhinitis Study Group: Double-blind, placebo-controlled study of azelastine (Astelin) nasal spray in patients with an unsatisfactory response to fexofenadine. *Presented at the annual meeting of the ACAAI in New Orleans, Louisiana, November, 2003.*
39. Wolfe J, LaForce C, Friedman B, Sokol W, Orevillo C, Ziehmer B, Till D, Stenglein S, Cioppa, GD: Formoterol 24 µg b.i.d. is not associated with increased serious asthma-related adverse events compared with formoterol 12 µg b.i.d. and placebo. *Presented at the AAAAI meeting, March 2004.*
40. Pinna J, LeDoux E, LaForce C, Jacobson K, Berkowitz R, Goldberg P, Lapidus R, Winder J, Atkinson D, Stahl E: Chronic-dose comparison of the efficacy and safety of albuterol HFA-MDI, albuterol HFA-BOI and Proventil® HFA in mild-to-moderate asthmatics. *Presented at the ATS meeting, May 2004.*

41. Busse W, LaForce C, Till D, Stenglein S: Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms. *Presented at the European Respiratory Society meeting, Copenhagen, Denmark September 2005.*
42. LaForce C: Effect of azelastine nasal spray on rhinitis symptoms and quality of life parameters in patients with an inadequate response to fexofenadine. *Presented in Annals of Allergy, Asthma & Immunology, Volume 94, January 2005, P251.*
43. Wolfe J, LaForce C, Ostrom N, Korenblat P, Orevillo C, Ziehmer B, Till D, Stenglein S: Formoterol 24 µg is not associated with an increase in serious asthma exacerbations in patients with persistent asthma. *J Allergy Clin Immunol Volume 115, Number 2, 598.*
44. Storms W, LaForce C, Ratner P: Role of ocular symptoms in seasonal allergies and the effect of Azelastine (Astelin®) nasal spray on ocular symptoms. *Presented at ACAAI meeting in Anaheim, California, November 4 – 9, 2005.*
45. Schenkel E, LaForce C, Staudinger H, Gates D: Mometasone furoate nasal spray once daily relieves ocular symptoms in patients with seasonal allergic rhinitis. *Presented at ACAAI meeting in Anaheim, California, November 4 – 9, 2005.*
46. Meltzer E, Kunjibettu S, Hall N, Berger W, LaForce C, Darken P, Shah T, Wingertzahn M: Efficacy and safety of ciclesonide (CIC) 200 µg once daily (OD) for the treatment of perennial allergic rhinitis (PAR). *J Allergy Clin Immunol, Vol 117, Number 2, S259, February 2006.*
47. Liu A, Zieger R, Welch M, Sorkness C, Chipps B, Guilbert T, Bernstein J, Mahr T, Ostrum N, LaForce C, Blaiss M, Stempel D, Burgess S, Crawford B, Jhingran P, Carranza-Rosenzweig J, and Manjunath R: Childhood asthma control test (ACT): Relationship scores to measures of asthma control. *Presented at ATS 2006 annual conference, May 22, 2006: A488.*
48. Langlands JM, LaForce, C: The effect of IPL512,602 in patients with mild-moderate persistent asthma (NEAT study). *Presented at the 2006 ATS annual conference, May 21, 2006: A80.*
49. Pearlman D, Greos L, LaForce C, Orevillo C, Armstrong G, Higgins M: Indacaterol, a novel once-daily β₂-agonist, provides full 24-hour bronchodilatory efficacy in patients with persistent asthma. *Presented at ATS 2006 annual conference, May 21, 2006:A79.*
50. LaForce C, Aisanov Z, Higgins M, Cameron R, Owen R: Indacaterol, a novel once-daily β₂-agonist, demonstrates efficacy and safety in patients with persistent asthma: a 7-day, multiple-dose study. *Poster presented at ATS 2006 annual conference, May 21, 2006: A79.*
51. Schaberg A, Meltzer E, LaForce C, Pearlman D, Ice J, LaVange L, Kellerman D: INS37217, a P2Y₂ receptor agonist, is a novel treatment for allergic rhinitis. *Presented at the ACAAI annual meeting in Philadelphia, PA, November 9-15, 2006.*

52. Meltzer EO, Berger WE, Chadwick SJ, Gross G, LaForce C, Garadi R, Crenshaw K, Wall GM: Patient comparison of sensory attributes of Olopatadine and Azelastine nasal sprays. *Poster presented at AAAAI annual meeting in San Diego, CA, February 26, 2007.*
53. Sorkness CA, Liu AH, Blaiss M, Mahr T, Chipps B, Ostrom N, LaForce C, Kaplan M, Rosa K, Manjunath R: Longitudinal validation of the childhood asthma control test. *Poster and abstract presented at ATS International Conference, San Francisco, CA May 18-23, 2007. Published in the American Journal of Respiratory and Critical Care Medicine, Vol 175, Abstracts Issue – April 2007, p A782.*
54. LaForce C, Skoner D: Resolution of symptoms in patients with acute respiratory infections receiving antibiotic therapy and Mucinex®D. *Submitted for presentation ACAAI annual meeting, Dallas, TX, November 8-14, 2007.*
55. Oppenheimer J, Kerwin E, LaForce C, Miller C, O'Dowd L, Goldman M: Asthma control with once-daily (qd) Budesonide/formoterol pressurized metered-dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice-daily (bid) Budesonide/formoterol pMDI. *To be published in the Journal of Allergy and Clinical Immunology, February 2008 supplement.*
56. Kerwin E, Oppenheimer J, LaForce C, Miller C, O'Dowd L, Goldman M: Effects on lung function of once-daily (qd) Budesonide and formoterol administered with once pressurized metered-dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice-daily (bid) Budesonide/formoterol pMDI. *To be presented at AAAAI 2008 meeting held March 14-18, 2008 in Philadelphia, PA. Also to be published in the Journal of Allergy and Clinical Immunology, February 2008 supplement.*
57. LaForce C, vanBavel J, Meltzer E, Chia V, Darken P, Wingertzahn M: Effectiveness of Ciclesonide nasal aerosol in adult and adolescent patients with seasonal allergic rhinitis (SAR). *Presented at ACAAI annual meeting, Dallas, Texas, November 7, 2007. Also to be presented at the AAAAI annual meeting on March 14-15, 2008 in Philadelphia, PA.*
58. Kerwin E, Oppenheimer J, LaForce C, Parasuraman B, Uryniak T, O'Dowd L, Goldman M: Asthma control and health-related quality of life (HRQL) after once-daily budesonide/formoterol pressurized metered-dose inhaler (BUD/.FM pMDI) in asthma patients stable with twice-daily BUD/FM pMDI. *Presented at 64th annual meeting of the American College of Allergy, Asthma and Immunology, November 8, 2007. Also to be presented at the ATS International Conference, Toronto, Canada, May 16-18, 2008.*
59. LaForce C, Korenblat P, Osborne P, Higgins M, Dong F: 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. *Submitted to Current Medical Research and Opinion, November 24, 2008.*

60. LaForce C, Janssens E, Parreno L, Iqbal A, Young D, Owen R, Higgins M, Kramer B: Sustained 24-hour efficacy of once-daily Indacaterol in patients with COPD. *Chest Journal*, October 2009, 136, 945.
61. Mohar D, LaForce C, Berger W, Lim J, Garris C, Prillaman B, Philpot E: Efficacy of fluticasone furoate nasal spray in conjunction with patient preference. *Annals of Allergy, Asthma and Immunology*, Poster abstract P334, January 2009, Vol 102, Number 1, Supplement 1, p A114.
62. Weinstein S, Meltzer EO, LaForce C, Korenblat P: Ciclesonide 80 µg twice daily or 160 µg once daily a.m. maintains variables of asthma control in adults with stable mild-to-moderate asthma previously treated with inhaled corticosteroid. *Annals of Allergy, Asthma and Immunology*, Poster abstract P73, January 2009, Vol 102, Number 1, Supplement 1, p A45.
63. van Noord JA, Buhl R, LaForce C, Martin C, Jones F, Dolker M, and Overend T: QVA149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD. *Poster presented at the European Society Conference, 12-16 September 2009, Vienna, Austria. Abstract presented at the COPD meeting held June 30 – July 2, 2010 in Birmingham UK, as well as the ATS meeting May 14-19, 2010.*
64. LaForce CF, Mahr TA, Goldberg P, Wall GM: Symptom relief with olopatadine hydrochloride nasal spray 0.6% in 6 to 11 year-old pediatric patients with seasonal allergic rhinitis. *Annals of Allergy, Asthma & Immunology*, Vol 103, No. 5, Supplement 3, November, 2009, A140. *Poster presented June 2010.*
65. Meltzer E, Nolte H, LaForce C: Low-dose Mometasone Furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma. *Annals of Allergy, Asthma and Immunology*, Vol 103, No. 5, Supplement 3, November 2009, A66. *Also Poster presented at ATS, May 14-19, 2010, New Orleans, LA. Poster also presented at World Congress of Asthma (WCA) November 3-6, 2010, Athens, Greece.*
66. Nelson H, LaForce C, Bonuccelli C, Radner F, Ottosson A, Carroll KJ, Andersson TL: Combined analysis of formoterol, safety data from double-blind, randomized, controlled trials of patients with asthma. *Annals of Allergy, Asthma and Immunology*, Vol 103, No. 5, Supplement 3, November 2009, A62.
67. LaForce C, Nelson H, Bonuccelli C, Radner F, Carroll KJ, Andersson TL: Effect on pulmonary function of budesonide/formoterol pressurized metered-dose inhaler (PMDI) versus budesonide by age group in randomized, controlled trials of patients with asthma. *Annals of Allergy, Asthma and Immunology*, Vol 103, No. 5, Supplement 3, November 2009, A61. *Poster presented June 2010.*

68. LaForce C, Weinstein C, Nathan R, Weinstein S, Staudinger H, Meltzer E: Patient satisfaction with a pressurized MDI integrated dose counter containing a fixed dose mometasone furoate/formoterol combination. *Annals of Allergy, Asthma and Immunology, Vol 103, No. 5, Supplement 3, November 2009, A60.*
69. Carr W, Tilles SA, Chipps BE, LaForce CF, Storms W, Meltzer EO, Lanier BQ: Comparison of olopatadine hydrochloride nasal spray 0.6% and azelastine hydrochloride nasal spray 0.1% in combination therapy with an intranasal steroid for the treatment of seasonal allergic rhinitis. *Annals of Allergy, Asthma and Immunology, Vol 103, No. 5 Supplement 3, November 2009, A28.*
70. Weinstein C, Staudinger H, LaForce C: Dose counter performance in adolescent and adult subjects with asthma or COPD. *Annals of Allergy, Asthma and Immunology, Vol 103, No. 5, Supplement 3, November 2009, A21.*
71. LaForce C, Claus R, Karafilidis J: Evaluation of the efficacy and safety of inhaled ciclesonide 160 µg once daily or 80 µg twice daily in adolescent subjects with asthma previously treated with an inhaled corticosteroid. *To be submitted to AANP, March 2010.*
72. LaForce C, Meltzer E, Nathan R, Weinstein S, Nolte H: Greater reduction in asthma symptom frequency during treatment with Mometasone Furoate/formoterol combination versus monocomponents and placebo. *To be presented at the American Academy of Allergy, Asthma and Immunology, March 18-22, 2011, San Francisco, CA.*
73. Pearlman DS, LaForce CF, Kaiser K: Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to its individual components. *Presented at European Respiratory Society, March 2011.*
74. Meltzer EO, Jacobs RL, LaForce CF, Dorinsky FM, Kelley L, Dunbar SA, Tantry SK: BDP HFA nasal aerosol 320 µg once daily is safe and effective in the treatment of nasal symptoms associated with perennial allergic rhinitis. *Presented ACAAI Annual Meeting, November 2011, p 359.*
75. LaForce C, Mohar D, Berger W, Raphael G, Huang H, Desai SY, Hinkle J, Bode F: A 26-week study evaluating rhinoconjunctivitis related quality of life in subjects with perennial allergic rhinitis following treatment with ciclesonide hydrofluoroalkane nasal aerosol. *Presented at ACAAI Annual Meeting, November 2011.*
76. LaForce C, Meltzer E, Nathan R, Weinstein S, Nolte H: Greater reduction in asthma symptom frequency during treatment with Mometasone Furoate/Formoterol Combination versus monocomponents and placebo. *Presented at AAAAI annual meeting, March 18-22, 2011, San Francisco, CA and presented at the World Congress of Asthma, 8/18/12, Quebec, Canada.*
77. Miller D, LaForce C, Finn A, Bateman E, Drda K, Platchford J, Broderick W, Fowler A,

- Gupta A, Wood C: Efficacy and safety of BI671800, an oral CRTHZ antagonist, as add-on therapy in poorly controlled asthma patients prescribed an inhaled steroid. *Presented at ERS Congress, Tuesday, 4 September 2012, 08:30-10:30.*
78. Pearlman D, LaForce C, Kaiser K: Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone. *Presented at PCRS Congress, UK, October 2012*
79. Hopkins RJ, Dackowski NF, Kaptur PE, Muse D, Sheldon E, LaForce C, Sari S, Rudge TL, Bernton E: Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of anthrax vaccine adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. *Published in PubMed.gov, Vaccine, 2013 Jun 26; 31 (30): 3051-8. E-pub 2013 May1.*
80. Feldman GJ, Bernstein JA, Hamilton A, Nivens C, Wang F, LaForce C: The 24-hour FEV₁ time profile of Olodaterol once daily (QD) via Respimat® and formoterol twice daily (BID) via Aerolizer® in patients with COPD: Results from two 6-week studies. *Submitted to Chest Journal, July 2013.*
81. Carr W, LaForce C, Hadley J, Gever L, Meltzer EO: Efficacy of MP29-02 (intranasal azelastine/fluticasone propionate) compared to commercial and non-commercial formulations of azelastine hydrochloride and fluticasone propionate for the treatment of seasonal allergic rhinitis (SAR). *Annals of Allergy, Asthma & Immunology, 2012 Annual Meeting, November 8-13 2012, Anaheim, California, P328, page A130-131.*
82. Skoner DP, LaForce CF, Nathan RA, Urdaneta ER, Zielinski MA, Sacavage SD, Franklin KB, Wu MM: Cetirizine 10 mg improves symptoms severity and quality of life in perennial allergic rhinitis. *Submitted Annals of Allergy, Asthma & Immunology, March 27, 2013, p 1-24.*
83. LaForce C, Herje N, Dorinsky P, Rickard K: Impact of fractional exhaled nitric oxide (FeNO) testing on asthma treatment decisions and costs. *Annals of Allergy, Asthma & Immunology, Volume 111, November 2013, P51, page A38.*
84. Siler TM, LaForce CF, Kianiford F, William J, Spangenthal S: Once-daily Indacaterol 75µg in moderate-to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect. *Int J Chron Pbstruct Pulmon Dis, September 1, 2014; 9:919-25. doi: 10.2147/COPD.S67356.eCollection 2014.*
85. LaForce C, Spangenthal S, Mota F, Henley M, Eckert J, Overend T, DiAndrea P: Twice-daily glycopyrronium provides clinically meaningful improvement in lung function and improves health status and dyspnea in COPD patients: The GEM1 study. *Presented at CHEST meeting held October 25-30, 2014, Austin, Texas.*

86. LaForce C, Brooks E, Herje N, Dorinsky P, Rickard K: Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic. *Ann Allergy Asthma Immunol, Dec 2014; 113 (6): 619-23. Epub 7/22/14.*
87. LaForce C, Pearle J, Feldman G, Spangenthal S, Eckert JH, Mota F, Henley M, D'Andrea P: Efficacy and safety of glycopyrronium in COPD patients with moderate-to-severe airflow limitation: the GEM1 study. *Presented at the ATS annual meeting held in Denver, Colorado, May 15-20, 2015.*
88. LaForce C, Miller D, Taveras H, Iverson H, O'Brien C, Raphael G: Albuterol multidose dry powder inhaler in patients 12 years and older with persistent asthma: 12 and 52 week safety. *Annals of Allergy Asthma & Immunology, Nov 2014, Vol 113 (p 73), A45.*
89. LaForce C, Taveras H, Iverson H: No tachyphylaxis following chronic use of albuterol multidose dry powder inhaler in children with asthma over 3 weeks. *Presented at ATS 2016 San Francisco International Conference, May 13-18, 2016.*
90. LaForce C, Pearle J, Feldman G, Spangenthal S, Eckert J, Mota F, Henley M, D'Andrea P: Efficacy and safety of glycopyrronium in COPD patients with moderate-to-severe airflow limitation: the GEM1 study. *Poster presented at ATS annual meeting, May 20, 2015, Denver, Colorado, posterboard #P512.*
91. Kerwin E, LaForce C, Pedinoff A, Di-Giovanni R, Jessup N, Henley M, D'Andrea P: Cardiovascular safety of Glycopyrronium in patients with moderate-to-severe COPD: pooled analysis from GEM1, GEM2, Flight 1 and Flight 2 studies. *Poster presented at CHEST 2015 Congress October 24-28, Montreal, Quebec, Canada. Poster presented at ATS 2016 Annual meeting, May 13-18, San Francisco, California.*
92. Ferguson GT, Fitzgerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, on behalf of the BISE study investigators: Benralizumab for mild to moderate, persistent asthma: The BISE Phase III study. *Podium presentation at ERS (European Respiratory Society) Congress, London,, September 7, 2016.*
93. Alving K, Anolik R, Crater G, LaForce C, Rickard K: Validation of a new portable exhaled nitric oxide analyzer: Randomized studies in asthma. *FeNO abstract presented at ACAAI annual meeting, San Francisco, CA, November 10-14, 2016. Also published online Pulm Ther DOI 10.1007/s4130-017-0032-8; February 24, 2017.*
94. Massanari M, Hanania N, Kassel E, LaForce C, and Rickard K: Measuring exhaled nitric oxide (FeNO) improves assessment of airway inflammation and guides stepwise treatment decisions. *Abstract presented at AAAAI annual meeting, March 6, 2017. Journal of Allergy and Clinical Immunology, Vol 139, Number 2, p 125.*
95. Nayak A, Berger W, LaForce C, Urdaneta E, Patel M, Franklin K and Wu M: Randomized,

placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. *Allergy Asthma Proc* 38, No 3: 222-230, May-June 2017; (doi: 10.2500/aap.2017.38.4050).

96. Rickard K, MacDonald-Berko M, Anolik R, Jain N, LaForce C, Wasserman R: Agreement between the 6 second and 10 second exhalation modes when measuring fractional exhaled nitric oxide (FeNO) in children aged 4 to 6 years with the NIOX VERO® device. *Poster presentation CHEST 2017 meeting, Metro Toronto Convention Center, November 1, 2017.*
97. Berman G, Amar N, LaForce C, Breazna A, Caracta C, Tantry S: Rapid onset of action on nasal symptoms and ocular symptom improvement with olopatadine/mometasone combination nasal spray in patients with seasonal allergic rhinitis. *Presented at AAAAI/WAO Joint Congress held March 2-5, 2018 in Orlando, Fl. Abstract also published in February 2018 online supplement to Journal of Allergy and Clinical Immunology.*
98. Jain N, Wasserman RL, LaForce C, Anolik R, MacDonald-Berko M, Rickard K: Fractional exhaled nitric oxide (FeNO) measurements with the NIOX VERO® in children 4 to 6 years old using the 6 and 10 second exhalation modes. *Presented at AAAAI/WAO Joint Congress held March 2-5, 2018 in Orlando, Fl.*
99. Tillinghast JP, LaForce CF, Hickey L, Small CJ: Patient-reported outcomes and quality of life improvements in patients with asthma receiving a new, breath-actuated beclomethasone dipropionate inhaler. *Presented at AAAAI/WAO Joint Congress held March 2-5, 2018 in Orlando, Fl.*
100. LaForce CF, Amar NJ, Breazna A, Caracta CF, Tantry SK: Rapid onset of action and improvement of nasal and ocular symptoms with olopatadine/mometasone combination nasal spray in patients with seasonal allergic rhinitis. *Abstract and poster presented at the Aspen Allergy Conference (AAC 2018), July 25, 2018.*
101. LaForce C, Surujbally R, Huyghe M, Burgess G, Mullinger B, Snape S: Pharmacokinetics of budesonide suspension delivered by the VR647 inhalation system in pediatric patients with wheezing, reactive airway disease or mild asthma. *Abstract to be presented at ATS Annual meeting held May 17-22, 2019 in Dallas, Texas.*
102. Maes A, Cappelletti C, Rossman K, Gillen M, LaForce C, Reisner C: A cumulative dose ($\leq 1440 \mu\text{g}$) study to evaluate the efficacy, PK, extrapulmonary PD, and safety of albuterol sulfate MDI in co-suspension delivery technology (AS MDI; PT007) in patients with asthma. *Presented at ATS Annual meeting held May 17-22, 2019 in Dallas, Texas.*
103. Wechsler ME, et al for the NHLBI AsthmaNet: Step-Up therapy in black children and adults with poorly controlled asthma. *New England Journal of Medicine, Sept 26, 2019; 381:1227-1239.*